UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

ALTUS PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)		0-51711 (Commission File Number)		04-3573277 (I.R.S. Employer Identification No.)

125 Sidney Street, Cambridge, Massachusetts (Address of principal executive offices)		02139 (Zip Code)

Registrant’s telephone number, including area code: (617) 299-2900

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 1.01. Entry into a Material Definitive Agreement.

     On December 19, 2006, Altus Pharmaceuticals Inc. (“Altus”) and Genentech, Inc. (“Genentech”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) to develop and commercialize ALTU-238, Altus’ long-acting, crystalline form of human growth hormone. On December 20, 2006, Altus filed a Current Report on Form 8-K announcing the execution of the Collaboration Agreement.

     This Current Report on Form 8-K is filed for the sole purpose of filing the Collaboration Agreement as an exhibit to this Current Report on Form 8-K. A copy of the Collaboration Agreement, as redacted in accordance with a request for confidential treatment, is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

     The foregoing description of the Collaboration Agreement is qualified in its entirety by reference to the full text of the Collaboration Agreement.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibits are furnished with this report:

Exhibit Number		Description
10.1		Collaboration and License Agreement dated December 19, 2006 by and between Altus Pharmaceuticals Inc. and Genentech, Inc. *

* Portions omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 1, 2007